Press Release
Bryan, Garnier & Co initiates coverage of Hybrigenics with a target price of €2.6
Paris, March 29, 2012 - Hybrigenics SA (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments against proliferative diseases, today announces the initiation of coverage of its stock by the investment bank Bryan, Garnier & Co with a target price of €2.6.
The full Bryan, Garnier & Co report can be found under Corporate / Investor Relations / Press
Releases on the Hybrigenics website.
About Hybrigenics - www.hybrigenics.com
Hybrigenics is a bio-pharmaceutical company listed (ALHYG) on Alternext (NYSE-Euronext) in Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative cancerous or non-cancerous diseases.
Hybrigenics' current development program is based on inecalcitol, a vitamin D receptor agonist active by oral administration. Oral inecalcitol is currently being studied in a clinical trial for the treatment of moderate-to-severe psoriasis. Oral inecalcitol is also planned to be tested in chronic lymphocytic leukemia patients. Oral inecalcitol has already shown excellent tolerance and strong presumption of efficacy for the first-line treatment of metastastic castrate-resistant prostate cancer in combination with Taxotere®, which is the current gold-standard chemotherapeutic treatment for this indication.
Hybrigenics has a research collaboration with Servier on
deubiquitinating enzymes and their inhibitors in oncology,
neurology, psychiatry, rheumatology, ophthalmology, diabetes
and cardiovascular diseases. Hybrigenics continues to build
on its pioneer research position in the field of
ubiquitin-specific proteases by exploring their role in other
areas of particular relevance, such as inflammation and
virology.
Hybrigenics Services SAS, a fully-owned subsidiary, is the
market leader in Yeast Two-Hybrid (Y2H) and related services
to identify, validate and inhibit protein interactions for
researchers in all areas of life sciences, using its ISO
9001-certified high-throughput Y2H screening platform, its
sophisticated bioinformatics tools and extensive database,
along with its chemical library and chemical screening
platform.
***
HYBRIGENICS is listed on the Alternext by NYSE Euronext Paris
ISIN: FR0004153930
Ticker: ALHYG
Hybrigenics Rémi Delansorne CEO
Tel.: +33 (0)1 58 10 38 00 investors@hybrigenics.com
NewCap.
Financial communication
Axelle Vuillermet / Pierre Laurent Tel.: +33 (0)1 44 71 94 94 hybrigenics@newcap.fr
1/1
distributed by | This press release was issued by Hybrigenics SA and was initially posted at http://www.hybrigenics.com/images/stories/corporate/_download/2012/pr_note%20bg_final_veng.pdf . It was distributed, unedited and unaltered, by noodls on 2012-03-29 10:17:15 AM. The issuer is solely responsible for the accuracy of the information contained therein. |